Yumanity Therapeutics Inc. (YMTX)

Stock Card

$1.89

$0.15 (8.62%)

As on 16-Dec-2022 16:00EDT

Market cap

$21 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

P/B Ratio

3.3

Div. Yield

0 %

Yumanity Therapeutics (YMTX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-32 Mln
ROE

-1.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.3
Debt to Equity

0
Book Value

$--
EPS

$-21.1
Face value

--
Shares outstanding

10,856,500

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Yumanity Therapeutics (YMTX)	-36.1	3.8	8.0	-38.8	-23.7	-17.6	--
BSE Sensex^*	-11.7	-4.8	1.7	-7.5	3.9	5.1	9.9
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 16-Dec-2022 | *As on 09-Sep-2026 | #As on 26-Oct-2023

Company	2021	2020	2019	2018	2017
Yumanity Therapeutics (YMTX)	-82.6	-62.7	-29.6	-44.2	-52.4
S&P Small-Cap 600	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Yumanity Therapeutics (YMTX)

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies... to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Read more

CEO, Pres & Director

Dr. Richard Peters M.D., Ph.D.
CEO, Pres & Director

Dr. Richard Peters M.D., Ph.D.
Headquarters

Boston, MA
Website

https://www.yumanity.com

FAQs for Yumanity Therapeutics (YMTX)

What is the current share price of Yumanity Therapeutics Inc (YMTX) Today?

The share price of Yumanity Therapeutics Inc (YMTX) is $1.89 (NASDAQ) as of 16-Dec-2022 16:00 EDT. Yumanity Therapeutics Inc (YMTX) has given a return of -23.67% in the last 3 years.

What is the current PB & PE ratio of Yumanity Therapeutics Inc (YMTX)?

Since, TTM earnings of Yumanity Therapeutics Inc (YMTX) is negative, P/E ratio is not available.
The P/B ratio of Yumanity Therapeutics Inc (YMTX) is 3.33 times as on 13-Jan-2023, a 32 discount to its peers’ median range of 4.90 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2021	-0.02	0.03
2020	-0.43	0.44
2019	--	--
2018	--	--
2021	-0.02	0.03

What is the 52 Week High and Low of Yumanity Therapeutics Inc (YMTX)?

The 52-week high and low of Yumanity Therapeutics Inc (YMTX) are Rs -- and Rs -- as of 09-Sep-2026.

What is the market cap of Yumanity Therapeutics Inc (YMTX)?

Yumanity Therapeutics Inc (YMTX) has a market capitalisation of $ 21 Mln as on 13-Jan-2023. As per SEBI classification, it is a Small Cap company.

Should I invest in Yumanity Therapeutics Inc (YMTX)?

Before investing in Yumanity Therapeutics Inc (YMTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.